| Cite this article: |
| LI Jingrong,LIANG Bingyi,PENG Wei,GAO Yongjian,LIN Bishan,ZENG Shan,TANG Chunhua,CHEN Jinxia,SU Weiwei.Study on the potential active components and molecular mechanism of Danggui Liuhuang Decoction in the treatment of ulcerative colitis based on bioinformatics and molecular docking technology[J].Journal Of Pharmaceutical Research,2022,41(9):561-569[Click to copy] |
|
| 摘要: |
| 目的 采用生物信息学和分子对接技术,探讨当归六黄汤(DGLHD)治疗溃疡性结肠炎(UC)的作用机制。方法 采用公共数据库(TCMSP、DrugBank和UniProt)寻找当归六黄汤的有效活性成分和相应的靶基因,构建DGLHD活性成分-靶蛋白相互作用网络。基于DisGeNET数据库、Genecards数据库和DrugBank数据库检索溃疡性结肠炎相关基因,获取当归六黄汤与溃疡性结肠炎的交集靶点基因。利用STRING在线数据库进行蛋白质-蛋白质相互作用关系(PPI)分析,获取核心靶点基因。采用Metascape在线数据库进行基因本体(GO)功能注释及KEGG通路富集。通过DiscoveryStudio 2016进行分子对接,确定药物活性成分与核心靶标相互作用的分子基础。结果 共筛选出82种活性化合物和132个交集靶基因。核心靶点基因涉及信号传导与转录激活因子3(STAT3)、TP53、AKT1、MAPK1、JUN和血管内皮生长因子A(VEGFA);通路富集主要为“肿瘤信号通路”、“糖尿病并发症中晚期糖基化终产物及其受体(AGE-RAGE)信号通路”“内分泌抵抗”、“NF-κB信号通路”、“Th17细胞分化”。分子对接结果表明,当归六黄汤核心活性成分可以通过氢键等相互作用与核心靶基因形成稳定的对接模式。结论 基于生物信息学和分子对接技术,筛选出当归六黄汤治疗溃疡性结肠炎的活性成分、核心靶点及主要信号通路,为当归六黄汤治疗溃疡性结肠炎提供了新的理论基础。 |
| 关键词: 当归六黄汤 溃疡性结肠炎 网络药理学 分子对接 |
| DOI:10.13506/j.cnki.jpr.2022.09.001 |
| 基金项目:佛山市重点领域科技攻关项目(No.2120001007987) |
|
Publication Date:September 25, 2022
|
|
| Study on the potential active components and molecular mechanism of Danggui Liuhuang Decoction in the treatment of ulcerative colitis based on bioinformatics and molecular docking technology |
| LI Jingrong1,LIANG Bingyi1,PENG Wei1,GAO Yongjian2,LIN Bishan2,ZENG Shan2,TANG Chunhua2,CHEN Jinxia2,SU Weiwei1 |
| (1.Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275,China;2.Sinopharm Group Guangdong Medi-Word Pharmaceutical Co.,Ltd.,Foshan 528305,China) |
| Abstract: |
| Objective To explore the molecular basis and mechanism of Danggui Liuhuang Decoction (DGLHD) in the treatment of ulcerative colitis (UC) by bioinformatics technology and molecular docking technology.Methods Effective active ingredients and corresponding targets of DGLHD were determined from the Public databases including TCMSP, DrugBank, and UniProt, and the drug ingredient-target network was constructed. The disease targets related to UC were obtained based on the GeneCards, DisGeNET and DrugBank databases. Then, the drug ingredient and disease targets were intersected to construct a protein-protein interaction network through the STRING database. The Metascape database was used for the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) pathway enrichment analyses of the core targets to explain the biological functions and signal pathways of the core proteins. Finally, molecular docking is performed through Discovery Studio 2016, so as to verify the binding ability between the active components of the drug and the core target protein.Results DGLHD has been screened out of 82 potentially effective active compounds and 132 intersected genes. Through topological analysis of PPI network, core targets was found including STAT3,TP53,AKT1,MAPK1,JUN and VEGFA. KEGG enrichment analysis showed that genes were particularly enriched in pathways in cancer, AGE-RAGE signaling pathway in diabetic complications, Hepatitis B, endocrine resistance, IL-17 signaling pathway, NF-κB signaling pathway and other pathways. Finally, the molecular docking verification demonstrates that some active components of the drug have good molecular docking and binding ability with the core target protein.Conclusion Based on the research foundation of bioinformatics and molecular docking technology, the active components and core target molecules of DGLHD for the treatment of UC are screened out, and the potential mechanism of DGLHD inhibiting UC is deeply explored. The results provide theoretical basis for DGLHD in the treatment of UC. |
| Key words: Danggui Liuhuang Decoction Ulcerative Colitis Bioinformatics Molecular Docking |